Loading data for TSHA — first visit, this takes a few seconds.
Taysha Gene Therapies, Inc.
5.16 +0.09 (1.78%)
5.24 +1.55%
- Capitalización de mercado
- $1.68B
- Volumen
- 3.15M
- Próxima fecha de resultados
- Nov 4, 2026
Taysha Gene Therapies, Inc. (TSHA): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | -100.00% |
| EPS | -$0.13 | -$0.02 | -62.50% |
Métricas
- Precio de compra
- 5.16
- Ingresos (TTM)
- 5.49M
- Beneficio neto (TTM)
- -150M
- 1.17
- -0.41
- n/a
- -11.16
- P/B (TTM)
- 6.99
- P/S (TTM)
- 306.53
- Fecha de resultados
- Nov 4, 2026
- Precio de venta
- 6.51
- Volumen
- 3,148,132
- Volumen medio (20D)
- 3,211,585
- Abierto
- 5.25
- Anterior Cerrar
- 5.07
- Rango del día
- 5.05 - 5.46
- Rango de 52 semanas
- 2.71 - 7.30
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Taysha Gene Therapies, Inc.
Ver perfil →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Industria Biotechnology
Sector Healthcare
IPO Fecha Sep 24, 2020
Empleados 99
Bolsa de Valores NasdaqGS
Símbolo bursátil TSHA
Sitio web https://www.tayshagtx.com